George Parides, DO
Pulmonary Disease · Mesa, AZNPI 1851379879
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $758,622 of the $912,624 with a category attached, or 83.1%. AstraZeneca accounts for 91.3% of it on its own, with 52 other manufacturers making up the rest. Among pulmonary disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,451 payments — averaging $628.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$833K
- Mylan Specialty L.p.$71K
- Verona Pharma, Inc.$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$571
- Boehringer Ingelheim$494
- GSK$476
- plus $5K from 47 others
What the payments were for
- Consulting fees$29,1693%
- Speaking & faculty fees$758,62283%
- Travel & lodging$96,45611%
- Food & beverage$28,3603%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$599,408
- AIRSUPRA$151,019
- Yupelri$68,827
- FASENRA$26,574
- BREZTRI AEROSPHERE$14,140
- DALIRESP$7,157
- SYMBICORT$5,883
- BEVESPI AEROSPHERE$3,517
- Ohtuvayre$2,000
- Prolastin-C$148
- DUPIXENT$123
How this compares
$912,624 in reported general payments places this provider in the 95th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 333 | $275,644 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 192 | $147,412 |
| Breo ElliptaFluticasone/Vilanterol | 93 | $48,407 |
| SymbicortBudesonide/Formoterol Fumarate | 135 | $43,177 |
| Spiriva RespimatTiotropium Bromide | 33 | $26,645 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $22,737 |
| Advair HfaFluticasone Propion/Salmeterol | 59 | $21,631 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 36 | $18,951 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 26 | $13,137 |
| Atrovent HfaIpratropium Bromide | 23 | $12,484 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 405 | $11,754 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $11,318 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 53 | $11,235 |
| BreynaBudesonide/Formoterol Fumarate | 50 | $11,043 |
| DuleraMometasone/Formoterol | 29 | $9,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $833,351 | $337,772504 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $476 | $216,422328 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $494 | $62,52089 claims |
| MerckDulera | $153 | $9,81729 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Mesa
- Mukesh AhluwaliaMesa$25K
- Steven FarberMesa$22K
- Rajat WaliaPhoenix$748K
- Abhinav MittalTucson$570K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
- Tony HodgesPhoenix$248K
- Richard SueGilbert$224K
- Mark GotfriedPhoenix$196K
- Rajeev SaggarPhoenix$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.